Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 24335106

Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Blood
Publication date
2014 Feb 27
First author
Hughes TP

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Hughes TP
      type
      Author
    2. name
      Saglio G
      type
      Author
    3. name
      Kantarjian HM
      type
      Author
    4. name
      Guilhot F
      type
      Author
    5. name
      Niederwieser D
      type
      Author
    6. name
      Rosti G
      type
      Author
    7. name
      Nakaseko C
      type
      Author
    8. name
      De Souza CA
      type
      Author
    9. name
      Kalaycio ME
      type
      Author
    10. name
      Meier S
      type
      Author
    11. name
      Fan X
      type
      Author
    12. name
      Menssen HD
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Hughes TP
      type
      Author
    2. name
      Saglio G
      type
      Author
    3. name
      Kantarjian HM
      type
      Author
    4. name
      Guilhot F
      type
      Author
    5. name
      Niederwieser D
      type
      Author
    6. name
      Rosti G
      type
      Author
    7. name
      Nakaseko C
      type
      Author
    8. name
      De Souza CA
      type
      Author
    9. name
      Kalaycio ME
      type
      Author
    10. name
      Meier S
      type
      Author
    11. name
      Fan X
      type
      Author
    12. name
      Menssen HD
      type
      Author
    bibliography ids
    1. nci-bib-34bc44cf292c415b368ec5be
    book metadata
    content sha256
    24bc2b023dccc50c7582e778c87750f13129bdac4e29cf4bfd5f91afac426736
    document type
    citation
    dois
    1. 10.1182/blood-2013-06-510396
    electronic publication date
    display
    2013 Dec 11
    precision
    day
    year
    2013
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:24335106
    immutable id
    pubmed:24335106@24bc2b023dccc50c7582e778c87750f13129bdac4e29cf4bfd5f91afac426736
    journal
    abbreviation
    Blood
    issn electronic
    1528-0020
    issn print
    0006-4971
    issue
    9
    name
    Blood
    nlm unique id
    7603509
    pages
    1353-60
    volume
    123
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      24335106
      provenance
      batch id
      af10498814d931b53231
      provider
      NCBI PubMed ESummary
      record sha256
      1449877fd6c3f1fecbd3fe01508c34649b35f8a0f650de5648dfc7edb303f5a6
      response sha256
      077a09272afe77e74d5ff01cb33335ddb8a638b7afbafb70ec20e837a0c85c7f
      retrieved at
      2026-09-09T23:47:00.193465+00:00
      publication date
      display
      2014 Feb 27
      precision
      day
      year
      2014
      publication types
      1. Journal Article
      2. Randomized Controlled Trial
      3. Research Support, Non-U.S. Gov't
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/24335106/
      title
      Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib.

      Preserved source evidence · Not medical advice